Skip to main content
SpringerLink
Log in

Canagliflozin: First Global Approval

  • R&D Insight Report
  • Published:
Drugs Aims and scope Submit manuscript

An Erratum to this article was published on 30 October 2013

Abstract

Canagliflozin (Invokana™), an oral selective sodium-glucose co-transporter 2 (SGLT2) inhibitor, is under global development with Mitsubishi Tanabe Pharma and Janssen Pharmaceuticals, a subsidiary of Johnson and Johnson, for the treatment of type 2 diabetes mellitus. SGLT2 are mainly located in the proximal tubule of the kidney and are involved in the reabsorption of filtered glucose from the glomeruli into the body. Inhibition of SGLT2 lowers blood glucose in an insulin independent manner as a consequence of blocking reabsorption of filtered glucose in the glomeruli, thereby increasing urinary excretion of glucose and, in turn, potentially reducing bodyweight. Canagliflozin is the first SGLT2 inhibitor to be approved in the USA and is under regulatory review in the EU. This article summarizes the milestones in the development of canagliflozin, leading to its first approval for use in adults with type 2 diabetes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Dokken B. The kidney as a treatment target for type 2 diabetes. Diabetes Spectr. 2012;25(1):29–36.

    Article  Google Scholar 

  2. Bailey CJ. Renal glucose reabsorption inhibitors to treat diabetes. Trends Pharmacol Sci. 2011;32(2):63–71.

    Article  PubMed  CAS  Google Scholar 

  3. Inzucchi SE, Bergenstal RM, Buse JM, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35:1364–79.

    Article  PubMed  CAS  Google Scholar 

  4. Neumiller JJ, White JR, Campbell RK. Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus. Drugs. 2010;70(4):377–85.

    Article  PubMed  CAS  Google Scholar 

  5. Janssen Pharmaceuticals Inc. Invokana™ (canagliflozin) tablets, for oral use: US prescribing information. 2013. http://www.janssenmd.com/pdf/invokana/PI-INVOKANA.pdf. Accessed 19 Apr 2013.

  6. European Medicines Agency. Forxiga (dapagliflozin): summary of product characteristics. 2013. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002322/WC500136026.pdf. Accessed 6 May 2013.

  7. Janssen Pharmaceuticals Inc. U.S. FDA approves canagliflozin (TA-7284) for the treatment of adult patients with type 2 diabetes. 2013. http://www.tanabe.co.jp. Accessed 5 Apr 2013.

  8. European Medicines Agency. Applications for new human medicines under evaluation by the Committee for Medicinal Products for Human Use: April 2013. 2013. http://www.ema.europa.eu/docs/en_GB/document_library/Report/2013/04/WC500142012.pdf. Accessed 19 Apr 2013.

  9. Janssen Research and Development LLC. Janssen Research and Development submits New Drug Application to U.S. FDA for canagliflozin to treat patients with type 2 diabetes. 2012. http://www.janssenrnd.com. Accessed 5 Apr 2013.

  10. Johnson and Johnson. A randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study to investigate the safety and efficacy of JNJ-28431754 in nondiabetic overweight and obese subjects [ClinicalTrials.gov identifier NCT00650806]. US National Institutes of Health, ClinicalTrials.gov. 2012. http://www.clinicaltrials.gov. Accessed 15 Apr 2013.

  11. Janssen Research and Development LLC. FDA Advisory Committee recommends approval of canagliflozin for treatment of adults with type 2 diabetes. 2013. http://www.janssenrnd.com. Accessed 5 Apr 2013.

  12. Janssen Pharmaceuticals Inc. Canagliflozin Advisory Committee Meeting: Endocrinologic and Metabolic Drugs Advisory Committee. 2013. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM336236.pdf. Accessed 6 May 2013.

  13. Janssen-Cilag International NV. Janssen submits European Marketing Authorisation Application for canagliflozin in type 2 diabetes. 2012. http://www.janssen-emea.com. Accessed 5 Apr 2013.

  14. Mitsubishi Tanabe Pharma Corporation, Daiichi Sankyo Co. Ltd. Daiichi Sankyo and Mitsubishi Tanabe Pharma establish strategic alliance to contribute to the treatment of diabetes in Japan. 2012. http://www.daiichisankyo.com. Accessed 5 Apr 2013.

  15. Mitsubishi Tanabe Pharma Corporation. A randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy, safety and tolerability of TA-7284 as monotherapy in the treatment of subjects with type 2 diabetes mellitus [ClinicalTrials.gov identifier NCT01413204]. US National Institutes of Health, ClinicalTrials.gov. 2013. http://www.clinicaltrials.gov. Accessed 5 Apr 2013.

  16. Inagaki N, Kondo K, Iwasaki T, et al. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2 (SGLT2) improves glycemic control and reduces body weight in Japanese type 2 diabetes mellitus (T2DM) [abstract no. 999-P]. Diabetes. 2011;60(Suppl):A274.

    Google Scholar 

  17. Mitsubishi Tanabe Pharma Corporation. A randomized, double-blind, placebo-controlled, parallel-group, multicenter, dose-ranging study in subjects with type 2 diabetes mellitus to evaluate the efficacy, safety and tolerability of orally administered SGLT2 inhibitorTA-7284 [ClinicalTrials.gov identifier NCT01022112]. US National Institutes of Health, ClinicalTrials.gov. 2010. http://www.clinicaltrials.gov. Accessed 5 Apr 2013.

  18. Mitsubishi Tanabe Pharma Corporation. An open-label, multicenter study to evaluate the long-term safety, tolerability and efficacy of TA-7284 in subjects with type 2 diabetes mellitus [ClinicalTrials.gov identifier NCT01387737]. US National Institutes of Health, ClinicalTrials.gov. 2010. http://www.clinicaltrials.gov. Accessed 5 Apr 2013.

  19. Mitsubishi Tanabe Pharma Corporation. Establishment of Mitsubishi Tanabe Pharma Corporation. 2007. http://www.mt-pharma.co.jp. Accessed 5 Apr 2013.

  20. Liang Y, Arakawa K, Ueta K, et al. Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models. PLoS One. 2012;7(2):e30555.

    Article  PubMed  CAS  Google Scholar 

  21. Mudaliar S, Ciaraldi TP, Sha S, et al. Canagliflozin lowers postprandial plasma glucose and insulin excursions by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion [abstract no. 244]. Diabetologia. 2012;55(Suppl.1):S108–9.

    Google Scholar 

  22. Sha S, Devineni D, Ghosh A, et al. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes Metab. 2011;13(7):669–72.

    Article  PubMed  CAS  Google Scholar 

  23. Sarich T, Devineni D, Ghosh A, et al. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, increases 24-hour urinary glucose excretion and reduces body weight in obese subjects over 2 weeks of treatment [abstract no. 874]. 46th Annual Meeting of the European Association for the Study of Diabetes; 20–24 Sep 2010; Stockholm.

  24. Polidori D, Sakai M, Devineni D. Exposure-response modeling of canagliflozin effects on the renal glucose threshold in subjects with type 2 diabetes (T2DM) [abstract no. 1072-P]. Diabetes. 2011;60(Suppl):A294.

    Google Scholar 

  25. Devineni D, Morrow L, Hompesch M, et al. Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. Diabetes Obes Metab. 2012;14(6):539–45.

    Article  PubMed  CAS  Google Scholar 

  26. Stein PP, Berg JK, Morrow L, et al. Canagliflozin (CANA), a sodium glucose co-transporter 2 (SGLT2) inhibitor, reduces post-meal glucose excursion in patients with type 2 diabetes mellitus (T2DM) by a non-renal mechanism [abstract no. 84-OR]. Diabetes. 2012;61(Suppl):A24.

    Google Scholar 

  27. Polidori D, Zhao Y, Sha S. Canagliflozin treatment improves beta cell function in subjects with type 2 diabetes [abstract no. 646-P]. 70th Annual Scientific Sessions of the American Diabetes Association; 25–29 Jun 2010; Orlando (FL).

  28. Wexler D, Vandebosch AN, Usiskin K, et al. Study of electrocardiogram intervals in healthy adults receiving single oral doses of canagliflozin [abstract no. 2177-PO]. 70th Annual Scientific Sessions of the American Diabetes Association; 25–29 Jun 2010; Orlando (FL).

  29. Devineni D, Curtin CR, Polidori D, et al. Canagliflozin, a sodium glucose co-transporter 2 [SGLT2] inhibitor: pharmacokinetics (PK) and pharmacodynamics (PD) in subjects with type 2 diabetes mellitus (T2DM) [abstract]. Clin Pharmacol Ther. 2012;91(Suppl):S98.

    Google Scholar 

  30. Stenlof K, Cefalu WT, Kim K-A, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab. 2013;15(4):372–82.

    Article  PubMed  CAS  Google Scholar 

  31. Janssen Research and Development LLC. A randomized, double-blind, placebo and active comparator-controlled, 4-arm, parallel group, multicenter study to evaluate the efficacy, safety, and tolerability of canagliflozin in the treatment of subjects with type 2 diabetes mellitus with inadequate glycaemic control on metformin monotherapy [ClinicalTrials.gov identifier NCT01106677]. US National Institutes of Health, ClinicalTrials.gov. 2013. http://www.clinicaltrials.gov. Accessed 22 Apr 2013.

  32. Niskanen L, Cefalu WT, Leiter LA, et al. Efficacy and safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, compared with glimepiride in patients with type 2 diabetes on background metformin [abstract no. 763]. Diabetologia. 2012;55(Suppl.1):S314.

    Google Scholar 

  33. Wilding J, Mathieu C, Deng L, et al. Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves glycaemia in subjects with type 2 diabetes inadequately controlled with metformin plus sulphonylurea [abstract no. 766]. Diabetologia. 2012;55(Suppl.1):S315–6.

    Google Scholar 

  34. Polidori D, Vercruysse F, Ferrannini E. Canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, improves indices of beta cell function in patients with type 2 diabetes on metformin plus sulphonylurea [abstract no. 761]. Diabetologia. 2012;55(Suppl.1):S313.

    Google Scholar 

  35. Schernthaner G, Gross JL, Rosenstock J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycaemic control with metformin plus a sulfonylurea. Diabetes Care. 2013. doi:10.2337/dc12-491/-/DCI.

  36. Guthrie R, Goldenberg R, Vijapurkar U, et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes mellitus on metformin and pioglitazone [abstract]. 4th World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension; 8–11 Nov 2012; Barcelona.

  37. Matthews, Fulcher G, Perkovic V, et al. Efficacy and safety of canagliflozin (CANA), an inhibitor of sodium glucose co-transporter 2 (SGLT2), added-on to insulin therapy +/− oral agents in type 2 diabetes [abstract no. 764]. Diabetologia. 2012;55(Suppl.1):S314–5.

    Google Scholar 

  38. Janssen Pharmaceuticals Inc. A efficacy, safety, and tolerability study of canagliflozin in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin alone or in combination with a sulfonylurea [ClinicalTrials.gov identifier NCT01381900]. US National Institutes of Health, ClinicalTrials.gov. 2013. http://www.clinicaltrials.gov. Accessed 22 Apr.

  39. Rosenstock J, Aggarwal N, Polidori D, et al. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care. 2012;35(6):1232–8.

    Article  PubMed  CAS  Google Scholar 

  40. Bode B, Stenlof K, Sullivan D, et al. Efficacy and safety of canagliflozin (CANA), a sodium glucose cotransporter 2 inhibitor (SGLT2), in older subjects with type 2 diabetes mellitus [abstract no. 765]. Diabetologia. 2012;55(Suppl.1):S315.

    Google Scholar 

  41. Yale JF, Bakris G, Wajs E, et al. Canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, improves glycaemic control and is well tolerated in type 2 diabetes mellitus (T2DM) subjects with moderate renal impairment [abstract no. 759]. Diabetologia. 2012;55(Suppl.1):S312.

    Google Scholar 

  42. Janssen Research and Development LLC. A safety and efficacy study of canagliflozin in older patients (55 to 80 years of age) with type 2 diabetes mellitus [ClinicalTrials.gov identifier NCT01106651]. US National Institutes of Health, ClinicalTrials.gov. 2013. http://www.clinicaltrials.gov. Accessed 22 Apr.

  43. Janssen Research and Development LLC. CANVAS: CANagliflozin cardioVascular Assessment Study [ClinicalTrials.gov identifier NCT01032629]. US National Institutes of Health, ClinicalTrials.gov. 2013. http://www.clinicaltrials.gov. Accessed 22 Apr 2013.

Download references

Author information

Authors and Affiliations

  1. Adis R&D Insight, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore 0754, Auckland, New Zealand

    Shelley Elkinson & Lesley J. Scott

Authors
  1. Shelley Elkinson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lesley J. Scott
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shelley Elkinson.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Elkinson, S., Scott, L.J. Canagliflozin: First Global Approval. Drugs 73, 979–988 (2013). https://doi.org/10.1007/s40265-013-0064-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-013-0064-9

Keywords

Search

Navigation